Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) announced on October 21 that its wholly-owned subsidiary, Brightgene Biomedical Technology (Wuxi) Co., Ltd., independently developed the Phase III clinical research plan for the weight-loss indication of BGM0504 injection, which has been approved by the Ethics Review Committee of Peking University People's Hospital, the leading hospital, and obtained the 'Ethics Review Approval Document of Peking University People's Hospital Ethics Review Committee'.

BGM0504 injection is an innovative type 1 chemical drug developed independently by the company, which is a dual agonist of GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide), not yet marketed domestically or internationally. BGM0504 injection can stimulate the downstream pathways of GIP and GLP-1, generating biological effects such as blood sugar control, weight loss, and treatment of non-alcoholic steatohepatitis (NASH), demonstrating potential for treating various metabolic diseases.